|
|
From the Leader's Desk I am delighted to share that one of our clients, Panbela, recently announced the issuance of a new patent in Japan for a novel process for producing SBP-101, a pancreatic cancer drug. The press release stated: "This patent, developed in collaboration with Syngene International Ltd., an integrated research, development, and manufacturing services company, claims a novel process with a reduced number of synthetic steps from seventeen to six to produce SBP-101, a lead investigational product. The patent is valid till 2039". In keeping with its reputation of being a partner for innovation, we are pleased to present Syngene SynVentTM. Our specialized platform for integrated discovery and preclinical development is led by a team of drug hunters with pharma and biotech experience across multiple therapeutic areas and modalities. These scientists, located primarily in the EU/UK or North America, form the cross-functional core team that partners with you to formulate detailed project plans with well-defined objectives and milestones. They then execute these plans in collaboration with our technical experts and project teams in India. Check out more on this unique platform in our 'In the Spotlight' section. We currently have 16 IDD client projects running on this platform. Also featured in this newsletter is our recent webinar on current approaches and trends to speed up drug discovery. The case study section discusses how Syngene screened 50,000 compounds using HTS against two different transcription factors and enabled rapid drug discovery. The scientific poster section on Targeted Protein Modulators is yet another interesting piece on the different assay platforms with differentiating approaches to targeted protein degraders, presented as a case study. Lastly, Syngene is attending CPhI Japan in Tokyo Big Sight between April 19 and 21. Don't forget to visit us at our booth #6B32. Happy reading. |
|
|
Best Wishes, |
|
|
In the Spotlight |
|
Syngene's SynVentTM: Integrated Drug Discovery platform |
|
Syngene offers fully integrated therapeutic discovery and development (IDD) services across small molecules and biologics through its proprietary platform, Syngene SynVentTM. The platform is designed to provide the most effective and efficient means to conduct target validation, translational interrogation, therapeutic discovery, and preclinical development. Further, our IDD services adhere to R&D timescales benchmarked to industry gold standards. |
|
|
Webinar |
|
Rapid Discovery: Accelerate drug discovery from hit ID to the clinic |
|
In this joint webinar with Axcelead, you will learn the 'right' approach to high throughput screening (HTS) to enable rapid drug discovery. Other topics include leveraging data-intensive tools like AI-ML to accelerate drug discovery across target identification, drug repurposing, DMTA cycles, etc. The webinar also covers other emerging technologies, such as microfluidics, organ-on-a-chip, and more. |
|
|
|
|
Case Study |
|
How Syngene screened inhibitors of protein-protein interaction in HTS mode for accelerated drug discovery |
|
A biotech company approached Syngene to develop an HTRF assay for screening inhibitors of protein-protein interaction in high throughput screening (HTS) mode. We were required to screen 50,000 compounds against two different transcription factors in a challenging megadalton-size multiprotein complex. Another requirement was to establish a counter-screen for identifying interfering compounds. |
|
|
Scientific Poster |
|
Targeted protein modulators: Cellular-to-ADME-to-PK/PD models and correlations |
|
The proteolysis targeting chimeras (PROTACs) and other similar targeted protein modulators (TPMs) have revolutionized drug discovery through their ability to drug the "undruggable". In this poster, Syngene presents the cellular translation to degradation and functional response across different assay platforms using a PROTAC tool, SynTAC-ERD, an estrogen receptor degrader. |
|
|
|
Meet us at |
|
|
|
|
|
© 2023, Syngene International Ltd. Syngene International Ltd. |